mii-exa-medikation-medication-statement-caelyx - MII IG Medikation v2027.0.0-ballot

MII IG Medikation
2027.0.0-ballot - Germany

MII IG Medikation - Downloaded Version 2027.0.0-ballot See the Directory of published versions

Example MedicationStatement: mii-exa-medikation-medication-statement-caelyx

English

status: Active

medication: Medication Caelyx pegylated liposomal 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung 1x25ml DSF N1

subject: Max Mustermann Male, DoB: 1965-03-14 ( https://www.medizininformatik-initiative.de/fhir/core/modul-medikation/sid/patient#12345)

effective: 2020-01-02 09:30:00+0100

dosage
timing: Once per 4 weeks
route: Intravenous use
DoseAndRates
- Dose[x]
* 50 mg/m2 (Details: UCUM codemg/m2 = 'mg/m2')

IG © 2019+ NUM-DIZ. Package de.medizininformatikinitiative.kerndatensatz.medikation#2027.0.0-ballot based on FHIR 4.0.1. Generated 2026-09-11
Links: Table of Contents | QA Report | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Legal notice
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.